6,842 Shares in Moderna, Inc. $MRNA Purchased by Apollon Wealth Management LLC

Apollon Wealth Management LLC bought a new stake in shares of Moderna, Inc. (NASDAQ:MRNA) in the 1st quarter, HoldingsChannel.com reports. The institutional investor bought 6,842 shares of the company’s stock, valued at approximately $348,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in MRNA. MUFG Securities EMEA plc bought a new position in Moderna in the 2nd quarter worth approximately $28,000. Flagship Harbor Advisors LLC bought a new stake in shares of Moderna in the fourth quarter valued at approximately $31,000. Ameriflex Group Inc. boosted its position in shares of Moderna by 3,775.0% in the third quarter. Ameriflex Group Inc. now owns 1,240 shares of the company’s stock valued at $32,000 after acquiring an additional 1,208 shares during the period. Cromwell Holdings LLC grew its stake in shares of Moderna by 39.7% in the fourth quarter. Cromwell Holdings LLC now owns 1,200 shares of the company’s stock worth $35,000 after acquiring an additional 341 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its stake in shares of Moderna by 148.3% in the second quarter. EverSource Wealth Advisors LLC now owns 1,341 shares of the company’s stock worth $37,000 after acquiring an additional 801 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Insider Buying and Selling at Moderna

In other news, Director Abbas Hussain sold 5,682 shares of Moderna stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $46.63, for a total transaction of $264,951.66. Following the sale, the director directly owned 12,066 shares in the company, valued at approximately $562,637.58. The trade was a 32.01% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Stephen Hoge sold 53,336 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the completion of the sale, the president directly owned 1,483,848 shares in the company, valued at approximately $76,225,271.76. The trade was a 3.47% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 125,088 shares of company stock valued at $6,193,713 over the last quarter. 10.80% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of brokerages recently issued reports on MRNA. Royal Bank Of Canada boosted their target price on shares of Moderna from $35.00 to $38.00 and gave the stock a “sector perform” rating in a research report on Monday, May 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Moderna in a research report on Friday, June 12th. Barclays boosted their price objective on shares of Moderna from $25.00 to $48.00 and gave the stock an “equal weight” rating in a report on Thursday, April 2nd. Piper Sandler upped their price objective on shares of Moderna from $69.00 to $77.00 and gave the company an “overweight” rating in a research report on Friday, June 26th. Finally, Jefferies Financial Group reiterated a “hold” rating on shares of Moderna in a research note on Thursday, June 18th. Two equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and five have issued a Sell rating to the stock. According to MarketBeat.com, Moderna has a consensus rating of “Reduce” and an average price target of $37.13.

Moderna Stock Performance

MRNA opened at $81.80 on Tuesday. The stock has a market cap of $32.46 billion, a PE ratio of -10.04 and a beta of 0.94. The company has a current ratio of 2.41, a quick ratio of 2.35 and a debt-to-equity ratio of 0.08. Moderna, Inc. has a 1 year low of $22.28 and a 1 year high of $85.60. The stock’s 50 day simple moving average is $54.08 and its 200-day simple moving average is $48.58.

Moderna (NASDAQ:MRNA) last issued its earnings results on Friday, May 1st. The company reported ($3.40) EPS for the quarter, missing the consensus estimate of ($3.02) by ($0.38). Moderna had a negative return on equity of 26.64% and a negative net margin of 143.55%.The firm had revenue of $389.00 million during the quarter, compared to the consensus estimate of $236.37 million. During the same period last year, the business earned ($2.52) earnings per share. The firm’s revenue for the quarter was up 260.2% compared to the same quarter last year. Sell-side analysts forecast that Moderna, Inc. will post -6.51 EPS for the current year.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.